+Compare
CHRS
Stock ticker:
NASDAQ
AS OF
Jul 1 closing price
Price
$7.83
Change
+$0.59 (+8.15%)
Capitalization
606.22M

CHRS Price Prediction, Coherus BioSciences AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jul 01, 2022

CHRS's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for CHRS turned positive on June 22, 2022. Looking at past instances where CHRS's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CHRS's RSI Indicator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on June 24, 2022. You may want to consider a long position or call options on CHRS as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .

CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CHRS entered a downward trend on June 28, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (48.309) is normal, around the industry mean (24.446). P/E Ratio (0.000) is within average values for comparable stocks, (93.841). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.919). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (1.974) is also within normal values, averaging (306.529).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

CHRS is expected to report earnings to fall 37.50% to -77 cents per share on August 10

Coherus BioSciences CHRS Stock Earnings Reports
Q2'22
Est.
$-0.77
Q1'22
Missed
by $0.59
Q4'21
Missed
by $0.14
Q3'21
Missed
by $0.14
Q2'21
Missed
by $0.19
The last earnings report on May 05 showed earnings per share of -124 cents, missing the estimate of -64 cents. With 826.63K shares outstanding, the current market capitalization sits at 606.22M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Global Blood Therapeutics (NASDAQ:GBT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.73B. The market cap for tickers in the group ranges from 2.5K to 250.34B. NONOF holds the highest valuation in this group at 250.34B. The lowest valued company is IMUND at 2.5K.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was -36%. EVFM experienced the highest price growth at 145%, while PCNTD experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -54%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -18 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a maker of biologic therapeutics for oncology and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
332
Web
N/A

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPGIX8.840.12
+1.38%
EuroPac Gold I
NGDRX20.730.25
+1.22%
Neuberger Berman Guardian R3
LCFLX13.190.14
+1.07%
Lord Abbett Focused Large Cap Value C
GFGEX10.890.07
+0.65%
Guardian Fundamental Glb Eq instl
INGFX31.900.01
+0.03%
Invesco Oppenheimer International Gr R5

CHRS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with SGMO. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then SGMO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+8.15%
SGMO - CHRS
61%
Loosely correlated
+3.38%
VBIV - CHRS
58%
Loosely correlated
-0.01%
XNCR - CHRS
55%
Loosely correlated
+5.44%
VXRT - CHRS
54%
Loosely correlated
+7.14%
ARWR - CHRS
54%
Loosely correlated
+2.13%
More